Melanoma research hub

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

This study looks at a medicine called pembrolizumab for children aged 6 months to 17 years with certain advanced cancers that haven't responded to other treatments. It's an immunotherapy that helps the body's immune system fight cancer, and researchers want to see if it can shrink these cancers.